了解ALS相关神经退行性疾病中的结构性不稳定和粉样聚合:对SOD1变体的in silico和实验分析
Nazanin Soleimanifard1, Bagher Seyedalipour1, Payam Baziyar1
1Department of Molecular and Cell Biology, Faculty of Basic Science, University of Mazandaran, Babolsar 47416-95447, Iran.
ACS chemical neuroscience
|October 9, 2025
概括
超氧化物脱酶1 (SOD1) 的金属缺乏和突变引发了蛋白质的错误折叠和聚合,导致像ALS这样的神经退行性疾病. 这项研究揭示了这些因素如何促进有害的SOD1聚合物的形成.
科学领域:
- 生物化学和分子生物学
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
背景情况:
- 蛋白质错误折叠和聚合是神经退行性疾病的标志.
- 超氧化物脱酶1 (SOD1) 需要金属离子来进行适当的折叠和功能;金属缺失 (apo形式) 会导致错误折叠和聚合.
- SOD1中的突变与肌缩性侧面硬化症 (ALS) 有关.
研究的目的:
- 调查突变和金属缺陷对SOD1聚合的影响.
- 阐明金属结合环在SOD1错折和粉样蛋白形成中的作用.
- 了解与ALS病原体中的SOD1聚合相关的结构和热力学变化.
主要方法:
- 计算方法包括分子动力学 (MD) 模拟.
- 实验技术:蛋白质二次结构词典 (DSSP),里埃变换红外光谱 (FTIR),圆二元化 (CD) 光谱,ANS光,刚果红色和提奥夫拉T (ThT) 光试验,以及传输电子显微镜 (TEM).
- 使用瓜尼丁化 (GdnHCl) 的热力学稳定性研究.
主要成果:
- 与holo-SOD1相比,Apo-SOD1表现出显著的形状差异和增加的β叶形成,表明聚合倾向.
- 突变和金属缺陷暴露了疏水口袋,并降低了热力学稳定性,促进了粉样和无形聚合物的形成.
- 实验和计算数据始终表明,在生理条件下,apo/holo SOD1 变体会诱导聚合物形成.
结论:
- 突变/金属缺乏,特别是在循环IV中,减少的二硫化物键协同破坏SOD1的稳定,推动聚合.
- 这些发现强调了金属化状态和结构完整性在SOD1聚合途径中的关键作用.
- 这项研究为开发针对ALS等神经退行性疾病中SOD1聚合的新疗法提供了基础.
更多相关视频
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
9.2K
11:57Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase
Published on: June 24, 2025
509
相关概念视频
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
